Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 When Administered to Adult and Elderly Subjects With and Without Underlying Medical Conditions.

Trial Profile

Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 When Administered to Adult and Elderly Subjects With and Without Underlying Medical Conditions.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; Influenza virus vaccine
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Novartis Vaccines; Seqirus
  • Most Recent Events

    • 13 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials. gov record.
    • 22 Dec 2014 Planned End Date changed from 1 Feb 2015 to 1 Apr 2015, as reported by ClinicalTrials. gov.
    • 22 Dec 2014 Planned primary completion date changed from 1 Feb 2015 to 1 Apr 2015, as reported by ClinicalTrials. gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top